Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Lily G. Bessette"'
Autor:
Elisabetta Patorno, Deborah J. Wexler, Helen Tesfaye, Robert J. Glynn, Lily G. Bessette, Lisette Koeneman, Sebastian Schneeweiss, Mehdi Najafzadeh, Anouk Deruaz-Luyet, Heidi Zakoul
Publikováno v:
Diabetes. 70
In the EMPA-REG OUTCOME trial empagliflozin (EMPA) reduced the risk of cardiovascular death, all-cause mortality, and hospitalization for heart failure in patients with type 2 diabetes (T2D) and established cardiovascular disease. The comparative saf
Autor:
Anouk Deruaz-Luyet, Mehdi Najafzadeh, Kimberly G. Brodovicz, Elisabetta Patorno, Lily G. Bessette, Martin Kulldorff, Ajinkya Pawar, Steven Sambevski, Sebastian Schneeweiss, Jessica M. Franklin
Publikováno v:
Diabetes. 68
EMPRISE studies the effectiveness, safety and healthcare utilization of empagliflozin (EMPA), a SGLT2 inhibitor, using data from Medicare and 2 U.S. commercial claims datasets (2014-2019). In an analysis on data from 2014-2016, we identified 17,551 p
Autor:
Nileesa Gautam, Ajinkya Pawar, Lily G. Bessette, Elisabetta Patorno, Mehdi Najafzadeh, Sebastian Schneeweiss, Anastasia Ustyugova, Kimberly G. Brodovicz, Anouk Deruaz-Luyet
Publikováno v:
Diabetes. 68
EMPRISE studies the comparative effectiveness, safety and health care resource utilization of empagliflozin (EMPA) in Medicare and 2 U.S. commercial claims datasets (2014-2019). In this first analysis, we evaluated healthcare costs and medications bu
Autor:
Elisabetta Patorno, Sebastian Schneeweiss, Ajinkya Pawar, Lily G. Bessette, Seoyoung C. Kim, Dae Hyun Kim, Brendan M. Everett, Robert J. Glynn
Publikováno v:
Diabetes. 68
Both SGLT2i inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA) have shown cardiovascular (CV) benefits in CV outcome trials among patients with type 2 diabetes (T2D) and established CV disease (CVD). Whether these agents are associated with d